Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers identified compound heterozygous variants in the MBTPS1 gene associated with ectodermal dysplasia features in a 14-year-old female, broadening the known disorder spectrum linked to these genetic mutations.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study found that nerve-mediated HDAC1 expression is necessary for blastema formation and limb regeneration in axolotls, and that inhibiting HDACs delays or inhibits this process.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study found that adults with β-thalassemia major had a significantly higher prevalence of skin, hair, and nail disorders compared to healthy controls, influenced by factors like age, gender, and ferritin levels.

This study found that TNFα inhibitors can induce psoriatic alopecia, highlighting that early diagnosis and discontinuation of the drugs in some cases may prevent irreversible scalp damage.

This study found that supraphysiological doses of testosterone alter endothelial relaxation pathways in hypertensive rats, with varied contributions from nitric oxide, prostanoids, and endothelium-derived hyperpolarizing factors, influenced by estrogen and dihydrotestosterone levels.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This review discusses the use of botulinum toxin as a treatment for chronic headache, highlighting its safety and acceptance among patients, but reports no new clinical results; the authors stress the need for comparative studies with standard treatments.

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This report discusses the challenges of interpreting bone mineral density in transgender individuals undergoing hormone therapy and highlights the lack of guidelines for assessing fracture risk or BMD results in this population.

This study found that subcutaneous administration of Botulinum toxin type A significantly reduced histamine-induced itch intensity and neurogenic inflammation in human skin compared to saline.

This open-label study suggests that combining valproate, lamotrigine, and a benzodiazepine can significantly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

In vivo using the C3H mouse model, this study observed that BST2 expression occurs before hair loss in alopecia areata and is followed by an increase in epidermal γδ T cell numbers.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This review discusses the intracellular activity of β-thymosins and their role in modulating the actin cytoskeleton, but it reports no new experimental results.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study found that acne tarda is prevalent, particularly among women and individuals with darker skin, with hormonal imbalances and endocrine disorders like PCOS commonly associated with its pathogenesis.

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

This correspondence comments on the unknown prevalence of permanent alopecia following high-dose docetaxel chemotherapy and highlights the need for further understanding and prevention strategies.

This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.

This review examines the molecular mechanisms by which the proapoptotic protein ARTS inhibits tumorigenesis and discusses prospects for developing drugs that mimic its function, with no new experimental results reported.

In this prospective clinical trial, azathioprine with steroid minipulse therapy and methotrexate with steroid minipulse therapy both improved hair regrowth in alopecia areata patients, but methotrexate showed slightly higher efficacy.

This study proposes that intranasal exposure to PTx and autoantigen in an animal model can trigger autoimmune disease, supporting the idea that subclinical nasal colonization by BP may cause alopecia areata.